NCT01862263 - Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes | Biotech Hunter

Enrollment

191

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Vildagliptin

Orally active and highly selective inhibitor of DPP-4

DRUG

Insulin

Long- acting human insulin analog indicated to improve glycemic control

DRUG

Placebo

Matching placebo of vildagliptin

Trial Locations (13)

14050

Novartis Investigative Site, Mexico City

38000

Novartis Investigative Site, Celaya

44150

Novartis Investigative Site, Guadalajara

44600

Novartis Investigative Site, Guadalajara

44670

Novartis Investigative Site, Guadalajara

52140

Novartis Investigative Site, Metepec

64020

Novartis Investigative Site, Monterrey

64710

Novartis Investigative Site, Monterrey

72190

Novartis Investigative Site, Puebla City

77500

Novartis Investigative Site, Cancún

80000

Novartis Investigative Site, Culiacán

06700

Novartis Investigative Site, Mexico City

07300

Novartis Investigative Site, Mexico City